Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.

This is your first of three free stories this month. Become a free or sustaining member to read unlimited articles, webinars and ebooks. The Hebron Road between Bethlehem and Jerusalem has changed ...

Checkpoint Therapeutics recently gained approval for cosibelimab, a PD-L1 inhibitor for advanced cSCC, but faces stiff competition and financial challenges. CKPT's pipeline includes cosibelimab, ...

The Seattle-Tacoma International (Sea-Tac) Airport had its busiest year in 2025 with 52.6 million passengers traveling between 30 different airlines. During peak travel times, it was common to see ...

Checkpoint Therapeutics, Inc. announced that the U.S. FDA approved its drug UNLOXCYT™ (cosibelimab-ipdl) in December 2024, making it the first and only anti-PD-L1 treatment for adults with advanced ...

Fintel reports that on January 13, 2025, D. Boral Capital initiated coverage of Checkpoint Therapeutics (NasdaqCM:CKPT) with a Buy recommendation. As of December 23, 2024, the average one-year price ...